MedTrace Logo

Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

NCT04169269 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2020-01-18

No results posted yet for this study

Summary

The objective of this study is to compare oral rivaroxaban with injectable enoxaparin in orthopaedic trauma patients to determine if orally administered rivaroxaban once daily carries greater compliance and overall satisfaction than enoxaparin self-administered by subcutaneous injection once daily.

Conditions

  • Deep Vein Thrombosis
  • Venous Thromboembolism

Interventions

DRUG

Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters

anticoagulant, subcutaneous injection

DRUG

Rivaroxaban 10 milligram Oral Tablet

anticoagulant, oral

Sponsors & Collaborators

  • Orthopaedic Trauma Association

    collaborator OTHER

  • Florida Orthopaedic Institute

    lead NETWORK

Principal Investigators

  • Hassan Mir, MD · Florida Orthopaedic Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-13
Primary Completion
2020-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04169269 on ClinicalTrials.gov